Skip to main content
Premium Trial:

Request an Annual Quote

Former Onyx Executive William Gerber Named DiaDexus President, CEO

Premium

SANTA CLARA, Calif.--DiaDexus, a new company here formed as a joint venture between SmithKline Beecham and Incyte Pharmaceuticals and dedicated to the discovery and commericalization of novel molecular diagnostic products, announced the appointment of William Gerber to the post of president and CEO. Gerber joined DiaDexus from Onyx Pharmaceuticals where he was vice-president and chief operating officer. Previous to that, Gerber was president of Chiron Diagnostics, held various positions with Cetus, and was a practicing physician.

SmithKline's Chief Science and Technology Officer George Poste said that Gerber will help DiaDexus emerge "as a formidable competitor in molecular diagnostics and pharmacogenomics." SmithKline and Incyte each hold a 50 percent equity interest in the company. Incyte provides DiaDexus with nonexclusive access to its human and microbial databases, bioinformatics capabilities, and certain array technologies.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.